The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of thymosin alpha-1 (TA1) are reviewed. Clinical trials of TA1 for chronic hepatitis B or C ...

ASADA is alleging the 34 players and one support person, no longer employed by Essendon, breached the AFL Anti-Doping Code through the use of the banned peptide thymosin ... given a legal version of ...

The product contains 1.6 mg of TA1 as a lyophilized powder for subcutaneous injection, 50 mg of mannitol, sodium phosphate buffer, and 1 mL of sterile water for injection as a diluent.